yuvaneshwari
☆    

India,
2019-04-18 11:12

Posting: # 20188
Views: 837
 

 Is FDA dissolution database more preferable to product specific FDA BE guidance? [Dissolution / BCS / IVIVC]

For a Oral solid dosage form [tablet and suspension], FDA dissolution database is recommending dissolution to be done at 25 degrees whereas, product specific FDA guidance for the same product is mentioning 37 degrees.

Which temperature should i need to adapt and follow for generic development ?


Edit: Please follow the Forum’s Policy[Helmut]
Vineeth KE
☆    

India,
2019-04-25 13:15

@ yuvaneshwari
Posting: # 20229
Views: 586
 

 Is FDA dissolution database more preferable to product specific FDA BE guidance?

» For a Oral solid dosage form [tablet and suspension], FDA dissolution database is recommending dissolution to be done at 25 degrees whereas, product specific FDA guidance for the same product is mentioning 37 degrees.
»
» Which temperature should i need to adapt and follow for generic development ?

For development purpose, it is advisable to follow 37 degrees, as it mimics in-vivo condition (For oral solid dosage form).

If the drug release is affected by temperature (due to API solubility/Surfactant Solubility in dissolution media/API degradation/gelling of excipients or any other reasons), it is better to consider the worst case scenario (25 or 37degrees).

For submission purpose, we need to evaluate in both the conditions as mentioned in FDA-Dissolution database & FDA-Product specific guidance.
Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
19,889 posts in 4,215 threads, 1,364 registered users;
online 5 (0 registered, 5 guests [including 2 identified bots]).
Forum time (Europe/Vienna): 08:47 CEST

I have no opinion about ‘incurred samples’ –
an expression which has no easily understandable
meaning for me in the English language.    Nick Holford

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5